Abstract
Hematological malignancies represent a significant portion among the diagnoses of neoplastic cells. Adoptive cell therapy with T cells genetically modified to express chimeric antigen receptors(CAR) has revolutionized the field, with promising and impressive results. However, there are still obstacles associated with the use of CAR-modified T cells, such as the need of autologous cells an…